Jdp patents expiration
1. Quzyttir patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8513259 | JDP | Non-sedating antihistamine injection formulations and methods of use thereof |
Feb, 2030
(5 years from now) | |
| US9119771 | JDP | Non-sedating antihistamine injection formulations and methods of use thereof |
Feb, 2030
(5 years from now) | |
| US9180090 | JDP | Non-sedating antihistamine injection formulations and methods of use thereof |
Feb, 2030
(5 years from now) | |
| US8314083 | JDP | Non-sedating antihistamine injection formulations and methods of use thereof |
Feb, 2030
(5 years from now) | |
| US8263581 | JDP | Non-sedating antihistamine injection formulations and methods of use thereof |
Feb, 2030
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 04, 2022 |
Drugs and Companies using CETIRIZINE HYDROCHLORIDE ingredient
Market Authorisation Date: 04 October, 2019
Treatment: Method of increasing peak plasma or onset of plasma concentration by intravenous injection in individuals in need of treatment for acute urticaria; Treatment of acute urticaria; Method of treatment in...
Dosage: SOLUTION;INTRAVENOUS
More Information on Dosage
QUZYTTIR family patents
